Poster Abstract Session:
147. Expanded Spectrum - New Antimicrobial Susceptibility Testing
Friday, October 6, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD

Tracks: Adult ID, Epidemiology and Infection Control, Investigative ID, Pediatric ID, Trainee

The Novel β-Lactamase Inhibitor, ETX-2514, in Combination with Sulbactam Effectively Inhibits Acinetobacter baumannii
Melissa D. Barnes, PhD; Christopher R. Bethel, MS; Joseph D. Rutter, BS; Focco Van Den Akker, PhD; Krisztina M. Papp-Wallace, PhD; Robert A. Bonomo, MD
Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
Robert K. Flamm, PhD; Leonard R. Duncan, Ph.D.; Dee Shortridge, Ph.D.; Jennifer I. Smart, Ph.D; Kamal Hamed, M.D., M.P.H.; Rodrigo E. Mendes, Ph.D.; Helio S. Sader, MD, PhD
  • IDWeek2017-ceftobiprole-BSI.pdf (702.8 kB)
  • Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
    Stephen Barat, PhD; David Angulo, MD; Katyna Borroto-Esoda, PhD; Mahmoud Ghannoum, PhD, FIDSA
    Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008-2016)
    Michael A. Pfaller, M.D.; Helio S. Sader, MD, PhD; Dee Shortridge, Ph.D.; Robert K. Flamm, PhD; Rodrigo E. Mendes, Ph.D.
    Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014–2016)
    Rodrigo E. Mendes, Ph.D.; Dee Shortridge, Ph.D.; Helio S. Sader, MD, PhD; Leonard R. Duncan, Ph.D.; Robert K. Flamm, PhD
  • IDWeek2017-TZD-BSI.pdf (535.6 kB)
  • Lysin CF-301 Demonstrates In Vitro Synergy with Conventional Antibiotics against Staphylococcus aureus
    Karen Sauve, B.S.; Alena Jandourek, M.D.; Cara Cassino, M.D.; Raymond Schuch, Ph.D.
    Synergistic antiviral activity of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, in combination with neuraminidase inhibitors in vitro.
    Mitsutaka Kitano, Ph.D.; Atsuko Yamamoto, MS; Takeshi Noshi, MS; Makoto Kawai, Ph. D.; Ryu Yoshida, Ph. D.; Akihiko Sato, Ph. D.; Takao Shishido, PhD; Akira Naito, Ph. D.
    Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014-2016)
    Rodrigo E. Mendes, Ph.D.; Dee Shortridge, Ph.D.; S J Ryan Arends, Ph.D.; Helio S. Sader, MD, PhD; Mariana Castanheira, PhD; Robert K. Flamm, PhD
    In Vitro Activity of Ceftolozane-Tazobactam Versus Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD study, 2008-2016
    Andrew Walkty, MD; Heather J. Adam, PhD; Melanie Baxter, MSc; Philippe Lagace-Wiens, MD; James Karlowsky, PhD; Daryl Hoban, PhD; George Zhanel, PhD
    In Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia
    Susanne Paukner, PhD; Robert K. Flamm, PhD; Jason Schuchert, PhD; Steven P. Gelone, PharmD; Helio S. Sader, MD, PhD
    Effects of Iclaprim and Trimethoprim on Exotoxin Production by Methicillin-resistant Staphylococcus aureus
    Amy Bryant, PhD; Eva Katahira, BA; David Huang, MD, PhD, FIDSA, FACP; Dennis Stevens, MD, PhD
    Activity of Delafloxacin When Tested against Bacterial Surveillance Isolates Collected in the US and Europe During 2014-2016 as Part of a Global Surveillance Program.
    Robert K. Flamm, PhD; Dee Shortridge, Ph.D.; Michael D. Huband, BS; Sandra McCurdy, M.S.; Michael A. Pfaller, M.D.
  • IDWeek2017-delafloxacin.pdf (654.9 kB)
  • In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
    Nathan P. Wiederhold, PharmD; James H. Jorgensen, PhD, FIDSA; Maria McElmeel, MT; Laura K. Najvar, BS; Gabriel Catano, MD; Thomas Patterson, MD, FIDSA, FACP
    Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
    Helio S. Sader, MD, PhD; Mariana Castanheira, PhD; Jennifer M. Streit, BS; Leonard R. Duncan, Ph.D.; Robert K. Flamm, PhD
    AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling
    Krisztina M. Papp-Wallace, PhD; Christopher R. Bethel, MS; Melissa D. Barnes, PhD; Joseph D. Rutter, BS; Magdalena A. Taracila, MS; Saralee Bajaksouzian, MS; Michael R. Jacobs, MD/PhD; Robert A. Bonomo, MD
    In vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Track Source: SIDERO-WT-2014/SIDERO-WT-2015
    Masakatsu Tsuji, Ph.D; Meredith Hackel, PhD, MPH; Roger Echols, MD, FIDSA; Yoshinori Yamano, Ph.D; Dan Sahm, PhD
    In Vitro Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens 
    Sandra Boyd, BS; Karen Anderson, BS MT(ASCP); Valerie Albrecht, MPH; Davina Campbell, MPH; Maria S. Karlsson, PhD; J. Kamile Rasheed, PhD
    Activity of Ceftolozane/tazobactam (C/T) and Ceftazidime/avibactam (CZA) against Extended-spectrum Beta-lactamase (ESBL)-producing Enterobacteriaceae and Multidrug-resistant (MDR) Pseudomonas aeruginosa Isolates
    Elizabeth B. Hirsch, PharmD, BCPS; Paola Zucchi, Ph.D; Nicole Cheung, PharmD student; Kyle Krevolin, MT; Christopher Emery, MD, D.(ABMM); Tiffany Bias, PharmD, BCPS, AAHIVP
    Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates
    Helio S. Sader, MD, PhD; Rodrigo E. Mendes, Ph.D.; Dee Shortridge, Ph.D.; Robert K. Flamm, PhD; Mariana Castanheira, PhD
  • IDWeek2017-AZT-AVI.pdf (1.5 MB)
  • Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying blaKPC Collected Worldwide
    Mariana Castanheira, PhD; Rodrigo E. Mendes, Ph.D.; Leonard R. Duncan, Ph.D.; Leah N. Woosley, B.S.; Robert K. Flamm, PhD
  • IDWeek2017-mero-vabor.pdf (1.9 MB)
  • Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing
    Mariana Castanheira, PhD; Lalitagauri M. Deshpande, PhD; Cory M. Hubler, BS; Rodrigo E. Mendes, Ph.D.; Alisa W. Serio, PhD; Kevin M. Krause, MBA; Robert K. Flamm, PhD
  • IDWeek2017-plazomicin.WGS.pdf (955.8 kB)
  • In-vivo efficacy of tigecycline-based therapy against Vibrio vulnificus sepsis: comparison with pre-existing regimens
    Seong Eun Kim, MD; Su-Mi Choi, MS; Hee Kyung Kim, MS; Tae Hoon Oh, MD; Uh Jin Kim, MD; Seung Ji Kang, MD; Kyung-Hwa Park, MD; Sook-In Jung, MD; Hee-Chang Jang, MD
    In Vitro and In Vivo Activity of Single and Dual Antimicrobial Agents Against KPC-producing Klebsiella pneumoniae
    Farzad Moussavi, MD; Sarath Nath, MD; Daniel Abraham, MD; David Landman, MD, FIDSA; John Quale, MD, FIDSA
  • IDSA 2017-worm poster.pdf (281.8 kB)
  • Activity of Ceftolozane-Tazobactam Against Global Pseudomonas Aeruginosa and Non-Susceptible Phenotypes: SMART 2016
    Sibylle Lob, MD, MPH; Meredith Hackel, PhD, MPH; Robert Badal, BS; Katherine Young, MS; Mary Motyl, PhD; Dan Sahm, PhD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.